Background Electronic cigarettes (‘vapes’) and other nicotine products such as oral pouches are increasingly used by adolescents. Consumption of these products by young people creates the potential for nicotine addiction and future use of tobacco, as well as associated respiratory problems including coughing, wheezing, and lung inflammation. At present, there are very few evidence-based vaping and nicotine prevention interventions targeting young people in the UK secondary school setting. Considering this gap, combined with rising normalisation of vaping in young people, the proposed development study aims to address a growing public health concern by creating a secondary school-based vaping and nicotine prevention intervention.   Materials and methods REVAMP will involve three phases. Phase 1 will include a review of existing literature on a) school-based electronic cigarettes/vaping prevention programmes globally, and b) causal and contextual factors associated with young people’s vaping. Reviews will include grey literature searches alongside synthesis and updates of existing systematic reviews. Phase 2 will involve a qualitative study, conducting semi-structured interviews and focus group discussions with secondary school students (n=16-20, age 11-13), school staff (n=6-8), parents and carers, and other stakeholders (n=20-26). These activities will explore the views and experiences of existing and future school-based approaches to vaping and nicotine consumption. In Phase 3 workshops will be held with students, school staff, parents and carers and wider stakeholders to consolidate findings from Phases 1 and 2 and collectively develop programme theory and intervention activities. Fieldwork for Phases 2-3 will take place in two secondary schools with profiles of high and low socioeconomic deprivation, respectively, within a single Scottish city. Findings will be disseminated through journal articles, conference presentations, local stakeholder events, and social media.   Discussion REVAMP presents a much-needed and timely pathway towards developing an evidence-based, school-based vaping prevention programme for young people in Scotland. This intervention will complement  UK-Wide regulatory efforts to reduce vaping and nicotine product access and appeal for young people. Strengths of this development study include engagement of a wide range of stakeholders, co-creation activities with young people, and extensive exploration of the international evidence base.

The authors have declared no competing interest.

Yes

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Not Applicable

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study is sponsored by ACCORD (Academic and Clinical Central Office for Research and Development) at University of Edinburgh

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Not Applicable

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Not Applicable

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Not Applicable

Data collected during this study will be stored in a pseudonymised format on a University of Edinburgh server. Access to the final trial dataset will be restricted to the Chief Investigator and research team. Anonymised study results will be made available upon reasonable request